TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12516646
Drug: Functional loading
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional loading of implants
Study: 8556789
Drug: Artemether (Art)
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether (Art) 6 mg/kg followed by repeated dosing every 15 days for 3 times.
Study: 2399780
Drug: Labetalol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.25 mg/kg in divided doses, followed by 0.50 mg/kg until blood pressure < 160/90 mmHg or total dose of 300 mg)
Study: 2399780
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (infusion starting at 0.5 micrograms/kg/min, titrated up to 6.0 micrograms/kg/min)
Study: 31577104
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement treatment
Study: 28375803
Drug: First-generation cephalosporin
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation cephalosporin (cefazolin; 1 g) (Group 2, n=191)
Study: 28375803
Drug: Second-generation cephalosporin
Normalized name: Second-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation cephalosporin (cefuroksim aksetil; 750 mg) (Group 3, n=186)
Study: 21221990
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (CC) - subjects refrained from strenuous exercise for 2 days prior to IET.
Study: 21221990
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise condition (REC) and Control condition (CC)
Study: 28374496
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg
Study: 12090591
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of leuprorelin acetate depot for 8 weeks
Study: 1932607
Drug: Ansaid (film‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ansaid (film‐coated 100 mg tablet)
Study: 1932607
Drug: Froben (sugar‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Froben (sugar‐coated 100 mg tablet)
Study: 28705885
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR≥3.0 ml/min per 1.73 m²
Study: 26562604
Drug: 40 mg/dl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/dl (low)
Study: 26562604
Drug: 65 mg/dl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg/dl (moderate)
Study: 26562604
Drug: 0 mg/dl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/dl (placebo)
Study: 19143752
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus cream 1% (n = 35)
Study: 19143752
Drug: Betamethasone cream
Normalized name: Betamethasone Cream
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone cream 0.1% (n = 35)
Study: 17500625
Drug: Original treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original treatment condition
Study: 15024982
Drug: Vaxigrip vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxigrip vaccine combined with Pneumo 23 and Avaxim vaccines
Study: 15024982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as those not receiving the combined vaccines)
Study: 12180720
Drug: etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg once daily
Study: 9834800
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg.kg‐1 (MIV 15)
Study: 9834800
Drug: Mivacurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.25 mg.kg‐1 (MIV 25)
Study: 9834800
Drug: Atracurium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.3 mg.kg‐1 (ATR 30)
Study: 9834800
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1 (ATR 50)
Study: 9834800
Drug: Vecuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.06 mg.kg‐1 (VEC 06)
Study: 9834800
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg.kg‐1 (VEC 10)
Study: 7626850
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 and Cyclophosphamide 1200 mg/m2
Study: 7626850
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 and Cyclophosphamide 900 mg/m2
Study: 2748870
Drug: Apomorphine (Apo)
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine (Apo) HCl 0.25, 0.5, 0.75, and 1.0 mg sc
Study: 2253535
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice a day
Study: 23690338
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin
Study: 31426703
Drug: Interarytenoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interarytenoid injection augmentation
Study: 28202370
Drug: Intramedullary nailing
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramedullary nailing & PRP injection/gel application (study group A)
Study: 28202370
Drug: Closed intramedullary
Normalized name: atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed intramedullary nailing & PRP injection (subgroup A1)
Study: 28202370
Drug: Open intramedullary
Normalized name: atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open intramedullary nailing & PRP gel with fibrin membrane (subgroup A2)
Study: 26096484
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of corticosteroids with lidocaine
Study: 21970138
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (PVB) with 0.2 ml/kg levobupivacaine
Study: 21970138
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block (CB) with 1 ml/kg levobupivacaine
Study: 16400054
Drug: Phenylalanine intake
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine intake of 48 mg x kg(‐1) x d(‐1)
Study: 16400054
Drug: Graded intakes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded intakes of phenylalanine (5, 10, 15, 25, 35, 45, 60, and 70 mg x kg(‐1) x d(‐1))
Study: 11284803
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg levocetirizine
Study: 21874559
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine
Study: 11284803
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dextrocetirizine
Study: 9815721
Drug: LSF, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSF, 1.5 mg/kg i.v. bolus every 6 h during IL-2 therapy
Study: 9815721
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 6 h during IL-2 therapy
Study: 3680816
Drug: Uniphyl (once-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (once-a-day theophylline formulation) after breakfast
Study: 3680816
Drug: Uniphyl (once-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (once-a-day theophylline formulation) after overnight fast
Study: 3680816
Drug: Reference theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference theophylline solution
Study: 27478057
Drug: Web-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapy tools and increased team meetings
Study: 19050530
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous dosing of cefazolin
Study: 19050530
Drug: Intraoperative dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative dosing by irrigation of cefazolin
Study: 16631656
Drug: Off-pump (beating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-pump (beating heart) and heparin 3 mg/kg (n = 20)
Study: 16631656
Drug: Off-pump (beating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-pump (beating heart) and heparin 1 mg/kg (n = 20)
Study: 9696209
Drug: Serum IgG
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum IgG antibodies to C. trachomatis in poor responders (44.7%)
Study: 10150262
Drug: Ampicillin/sulbactam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (1.0 to 2.0 g ampicillin plus 0.5 to 1.0 g sulbactam every 6 hours)
Study: 10150262
Drug: Cefoxitin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1.0 to 2.0 g every 6 hours)
Study: 3190058
Drug: Zidovudine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (2 g/d for 2 weeks, and 1 g/d for 6 weeks)
Study: 31099167
Drug: Waiting-list group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list group maintaining daily routines
Study: 23752604
Drug: G-CSF therapy
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF therapy and CVC-related sepsis
Study: 16922471
Drug: Pre-treatment levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment levels
Study: 21765206
Drug: Alprazolam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (low and high doses)
Study: 16648504
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan 1.7 mg/m2/d x 5 with IV cisplatin 60 mg/m2 on day 5 (TC)
Study: 16648504
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide 100 mg/m2/d x 3 with IV cisplatin 80 mg/m2 on day 1 (PE)
Study: 30807294
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy
Study: 30848868
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily short-message-based re-education (SMRE)
Study: 30848868
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral and written instructions)
Study: 16198059
Drug: risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (4 mg/day)
Study: 15349006
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg for 8 weeks
Study: 11286468
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day, n = 84)
Study: 11286468
Drug: Toremifene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (40 mg/day, n = 83)
Study: 9200375
Drug: Newborns (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newborns (mean leptin concentration 10.57 ng/mL)
Study: 9200375
Drug: Children in
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in Tanner stages 1 and 2 (mean leptin concentration 3.04 ng/mL)
Study: 9200375
Drug: Mothers (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers (mean leptin concentration 28.8 ng/mL)
Study: 7905185
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Roxatidine acetate once daily, late in the evening (between 10.00 p.m. and 11.00 p.m.)
Study: 7905185
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Roxatidine acetate once daily, early in the evening (between 6.00 p.m. and 7.00 p.m.)
Study: 7905185
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (bedtime and early evening administration)
Study: 17371783
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg daily)
Study: 2952436
Drug: Bendrofluazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (2.5 mg daily)
Study: 26577062
Drug: Mirtazapine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (single dose)
Study: 23864536
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (n = 68)
Study: 19897276
Drug: Choline supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplement (1500 mg twice daily)
Study: 20137476
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone
Study: 2977272
Drug: Zoladex (LH-RH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (LH-RH analogue), administered every 28 days
Study: 29346524
Drug: Multidisciplinary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary intervention (exercise training, hyperproteic nutritional shakes, memory training, medication review)
Study: 12358242
Drug: Parenteral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral feeding (group TPN), n = 27
Study: 7059489
Drug: Sherry (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sherry (40 ml) after placebo
Study: 31157682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ROTEM values with protein C or antithrombin
Study: 25715353
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate and high-dose prednisolone (tapering for 2 weeks)
Study: 22982689
Drug: Pharmacist-initiated reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-initiated reduction of ADS score after multidisciplinary drug reviews
Study: 19554274
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of connective tissue massage, Mc Mennell joint manipulation, and home exercise programme
Study: 15054673
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV ondansetron before anesthetic induction plus 4 mg IV immediately before extubation (experimental group)
Study: 15054673
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV ondansetron before anesthetic induction (control group)
Study: 11642472
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg and 20 mg)
Study: 7872224
Drug: 3.9 g
Normalized name: aspirin 3.9 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 g konjac glucomannan daily for 4 weeks
Study: 28673312
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content (RNC) cigarettes (11.6 to 0.2 mg/cigarette)
Study: 28673312
Drug: Usual nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual nicotine content (UNC) cigarettes (11.6 mg/cigarette)
Study: 18266532
Drug: Structural ecosystems
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural ecosystems therapy (SET)
Study: 16780497
Drug: Topical photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical photodynamic therapy (PDT) weekly for 4 weeks
Study: 16780497
Drug: Topical paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin twice-daily for 4 weeks
Study: 11000341
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily plus calcium supplementation 500 mg daily
Study: 11000341
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus calcium supplementation 500 mg daily
Study: 1377290
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) followed by serum PSA determination
Study: 30451595
Drug: EFV/FTC/TDF therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV/FTC/TDF therapy
Study: 29632533
Drug: M72/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01 vaccine
Study: 19233181
Drug: High-dose celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose celecoxib (400 mg twice daily)
Study: 19233181
Drug: Low-dose celecoxib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose celecoxib (200 mg twice daily)
Study: 19706349
Drug: Fentanyl HCl
Normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl HCl iontophoretic transdermal system (ITS)
Study: 17505380
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of morphine provided by an intravenous patient-controlled analgesia (IV PCA) pump
Study: 15040557
Drug: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg)
Study: 15040557
Drug: Malarone (atovaquone/proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malarone (atovaquone/proguanil 3000/1200 mg)
Study: 11315718
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy regimens (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Study: 9253783
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing of epoetin alfa
Study: 9253783
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of epoetin alfa
Study: 8416444
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g dose of ampicillin
Study: 3940480
Drug: Prednisolone, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 60 mg/d for 2 weeks, then 30 mg/d for another 2 weeks
Study: 28123163
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg twice daily for 21 days during acute treatment phase
Study: 28123163
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily for up to 12 months after initial treatment
Study: 22525171
Drug: Patching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching therapy (1 hour daily per month of age until 8 months, then 50% of waking hours)
Study: 22525171
Drug: Patching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching therapy
Study: 17513629
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 4 g IV
Study: 17658628
Drug: Acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl L-carnitine (ALC)
Study: 8053025
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin derivatives in combination with mefloquine for primary treatment of uncomplicated malaria
Study: 8053025
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin derivatives for treatment of recrudescent infections
Study: 8053025
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin derivatives for patients with high parasitaemias (> or = 4%) but no clinical evidence of severity
Study: 8053025
Drug: Parenteral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral formulation of artemether given rectally
Study: 14752069
Drug: Short chemotherapy
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short chemotherapy (6 months)
Study: 14752069
Drug: Long chemotherapy
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long chemotherapy (15 months)
Study: 10510952
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg t.d.s.)
Study: 9090332
Drug: High-dose olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose olanzapine
Study: 9090332
Drug: Haloperidol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10-20 mg/day)
Study: 2945785
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g elemental calcium/day)
Study: 12586130
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg/day
Study: 14516890
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/day + warfarin
Study: 6427848
Drug: Lithicarb (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithicarb (standard lithium carbonate preparation)
Study: 6427848
Drug: Priadel (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priadel (sustained-release lithium carbonate preparation)
Study: 25466382
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg once daily
Study: 26800231
Drug: Baricitinib 10
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 10 mg
Study: 28474817
Drug: Insulin-treated DM
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated DM (ITDM)
Study: 28474817
Drug: Non-insulin-treated DM
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin-treated DM (NITDM)
Study: 25934656
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus stenting